Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors.
Identifieur interne : 000621 ( Main/Exploration ); précédent : 000620; suivant : 000622Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors.
Auteurs : Ashley M. Hopkins [Australie] ; Ganessan Kichenadasse [Australie] ; Ross A. Mckinnon [Australie] ; Andrew Rowland [Australie] ; Michael J. Sorich [Australie]Source :
- Seminars in oncology [ 1532-8708 ]
Descripteurs français
- KwdFr :
- Anticorps monoclonaux humanisés (pharmacologie), Anticorps monoclonaux humanisés (usage thérapeutique), Antinéoplasiques immunologiques (pharmacologie), Antinéoplasiques immunologiques (usage thérapeutique), Charge tumorale (MeSH), Essais cliniques comme sujet (MeSH), Estimation de Kaplan-Meier (MeSH), Humains (MeSH), Immunomodulation (effets des médicaments et des substances chimiques), Pronostic (MeSH), Résultat thérapeutique (MeSH), Thérapie moléculaire ciblée (MeSH), Tumeurs du poumon (anatomopathologie), Tumeurs du poumon (immunologie), Tumeurs du poumon (mortalité), Tumeurs du poumon (traitement médicamenteux).
- MESH :
- anatomopathologie : Tumeurs du poumon.
- effets des médicaments et des substances chimiques : Immunomodulation.
- immunologie : Tumeurs du poumon.
- mortalité : Tumeurs du poumon.
- pharmacologie : Anticorps monoclonaux humanisés, Antinéoplasiques immunologiques.
- traitement médicamenteux : Tumeurs du poumon.
- usage thérapeutique : Anticorps monoclonaux humanisés, Antinéoplasiques immunologiques.
- Charge tumorale, Essais cliniques comme sujet, Estimation de Kaplan-Meier, Humains, Pronostic, Résultat thérapeutique, Thérapie moléculaire ciblée.
English descriptors
- KwdEn :
- Antibodies, Monoclonal, Humanized (pharmacology), Antibodies, Monoclonal, Humanized (therapeutic use), Antineoplastic Agents, Immunological (pharmacology), Antineoplastic Agents, Immunological (therapeutic use), Clinical Trials as Topic (MeSH), Humans (MeSH), Immunomodulation (drug effects), Kaplan-Meier Estimate (MeSH), Lung Neoplasms (drug therapy), Lung Neoplasms (immunology), Lung Neoplasms (mortality), Lung Neoplasms (pathology), Molecular Targeted Therapy (MeSH), Prognosis (MeSH), Treatment Outcome (MeSH), Tumor Burden (MeSH).
- MESH :
- chemical , pharmacology : Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological.
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological.
- drug effects : Immunomodulation.
- drug therapy : Lung Neoplasms.
- immunology : Lung Neoplasms.
- mortality : Lung Neoplasms.
- pathology : Lung Neoplasms.
- Clinical Trials as Topic, Humans, Kaplan-Meier Estimate, Molecular Targeted Therapy, Prognosis, Treatment Outcome, Tumor Burden.
Abstract
BACKGROUND
Baseline tumor size (BTS) was recently indicated as prognostic of overall survival (OS) in patients advanced melanoma treated with pembrolizumab. We review the association between BTS and OS/progression-free survival (PFS) in patients with a diagnosis of advanced non-small-cell lung cancer (NSCLC) treated with atezolizumab.
METHODS
Data from 1,461 patients with a diagnosis of advanced NSCLC enrolled in the OAK, POPLAR, BIRCH, and FIR trials and treated with atezolizumab were pooled and analyzed. Using Cox proportional hazards regression, we modeled the association between baseline SLD and survival outcomes. Multivariable analyses were adjusted for pretreatment ECOG PS, age, sex, race, smoking status, histology, count of prior treatments, PDL1 expression, serum LDH levels, and the presence of liver, lung, or brain lesions.
RESULTS
On univariable and multivariable analysis, baseline sum of the longest diameters of target lesions (SLD) was identified as significantly associated with OS (hazard ratio [95% confidence interval] per decimeter: 1.64 [1.41-1.91], P < .001) and PFS (1.21 [1.07-1.38], P = .003). Median OS were 16 months versus 10 months for baseline SLD < median, versus baseline SLD ≥ median, respectively. Median PFS were 4 months versus 3 months, respectively.
CONCLUSIONS
Large BTS was identified as an independent prognostic factor of worse OS and PFS, raising the need to evaluate atezolizumab as an earlier NSCLC treatment in future trials.
DOI: 10.1053/j.seminoncol.2019.10.002
PubMed: 31735362
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors.</title><author><name sortKey="Hopkins, Ashley M" sort="Hopkins, Ashley M" uniqKey="Hopkins A" first="Ashley M" last="Hopkins">Ashley M. Hopkins</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia. Electronic address: ashley.hopkins@flinders.edu.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Flinders University, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author><author><name sortKey="Kichenadasse, Ganessan" sort="Kichenadasse, Ganessan" uniqKey="Kichenadasse G" first="Ganessan" last="Kichenadasse">Ganessan Kichenadasse</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Flinders University, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author><author><name sortKey="Mckinnon, Ross A" sort="Mckinnon, Ross A" uniqKey="Mckinnon R" first="Ross A" last="Mckinnon">Ross A. Mckinnon</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Flinders University, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author><author><name sortKey="Rowland, Andrew" sort="Rowland, Andrew" uniqKey="Rowland A" first="Andrew" last="Rowland">Andrew Rowland</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Flinders University, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author><author><name sortKey="Sorich, Michael J" sort="Sorich, Michael J" uniqKey="Sorich M" first="Michael J" last="Sorich">Michael J. Sorich</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Flinders University, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019 Aug - Oct</date><idno type="RBID">pubmed:31735362</idno><idno type="pmid">31735362</idno><idno type="doi">10.1053/j.seminoncol.2019.10.002</idno><idno type="wicri:Area/Main/Corpus">000610</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000610</idno><idno type="wicri:Area/Main/Curation">000610</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000610</idno><idno type="wicri:Area/Main/Exploration">000610</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors.</title><author><name sortKey="Hopkins, Ashley M" sort="Hopkins, Ashley M" uniqKey="Hopkins A" first="Ashley M" last="Hopkins">Ashley M. Hopkins</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia. Electronic address: ashley.hopkins@flinders.edu.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Flinders University, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author><author><name sortKey="Kichenadasse, Ganessan" sort="Kichenadasse, Ganessan" uniqKey="Kichenadasse G" first="Ganessan" last="Kichenadasse">Ganessan Kichenadasse</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Flinders University, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author><author><name sortKey="Mckinnon, Ross A" sort="Mckinnon, Ross A" uniqKey="Mckinnon R" first="Ross A" last="Mckinnon">Ross A. Mckinnon</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Flinders University, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author><author><name sortKey="Rowland, Andrew" sort="Rowland, Andrew" uniqKey="Rowland A" first="Andrew" last="Rowland">Andrew Rowland</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Flinders University, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author><author><name sortKey="Sorich, Michael J" sort="Sorich, Michael J" uniqKey="Sorich M" first="Michael J" last="Sorich">Michael J. Sorich</name><affiliation wicri:level="1"><nlm:affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>College of Medicine and Public Health, Flinders University, Adelaide</wicri:regionArea><wicri:noRegion>Adelaide</wicri:noRegion></affiliation></author></analytic><series><title level="j">Seminars in oncology</title><idno type="eISSN">1532-8708</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal, Humanized (pharmacology)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antineoplastic Agents, Immunological (pharmacology)</term><term>Antineoplastic Agents, Immunological (therapeutic use)</term><term>Clinical Trials as Topic (MeSH)</term><term>Humans (MeSH)</term><term>Immunomodulation (drug effects)</term><term>Kaplan-Meier Estimate (MeSH)</term><term>Lung Neoplasms (drug therapy)</term><term>Lung Neoplasms (immunology)</term><term>Lung Neoplasms (mortality)</term><term>Lung Neoplasms (pathology)</term><term>Molecular Targeted Therapy (MeSH)</term><term>Prognosis (MeSH)</term><term>Treatment Outcome (MeSH)</term><term>Tumor Burden (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps monoclonaux humanisés (pharmacologie)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Antinéoplasiques immunologiques (pharmacologie)</term><term>Antinéoplasiques immunologiques (usage thérapeutique)</term><term>Charge tumorale (MeSH)</term><term>Essais cliniques comme sujet (MeSH)</term><term>Estimation de Kaplan-Meier (MeSH)</term><term>Humains (MeSH)</term><term>Immunomodulation (effets des médicaments et des substances chimiques)</term><term>Pronostic (MeSH)</term><term>Résultat thérapeutique (MeSH)</term><term>Thérapie moléculaire ciblée (MeSH)</term><term>Tumeurs du poumon (anatomopathologie)</term><term>Tumeurs du poumon (immunologie)</term><term>Tumeurs du poumon (mortalité)</term><term>Tumeurs du poumon (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Antineoplastic Agents, Immunological</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Antineoplastic Agents, Immunological</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Immunomodulation</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Immunomodulation</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Antinéoplasiques immunologiques</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Antinéoplasiques immunologiques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Molecular Targeted Therapy</term><term>Prognosis</term><term>Treatment Outcome</term><term>Tumor Burden</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Charge tumorale</term><term>Essais cliniques comme sujet</term><term>Estimation de Kaplan-Meier</term><term>Humains</term><term>Pronostic</term><term>Résultat thérapeutique</term><term>Thérapie moléculaire ciblée</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Baseline tumor size (BTS) was recently indicated as prognostic of overall survival (OS) in patients advanced melanoma treated with pembrolizumab. We review the association between BTS and OS/progression-free survival (PFS) in patients with a diagnosis of advanced non-small-cell lung cancer (NSCLC) treated with atezolizumab.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Data from 1,461 patients with a diagnosis of advanced NSCLC enrolled in the OAK, POPLAR, BIRCH, and FIR trials and treated with atezolizumab were pooled and analyzed. Using Cox proportional hazards regression, we modeled the association between baseline SLD and survival outcomes. Multivariable analyses were adjusted for pretreatment ECOG PS, age, sex, race, smoking status, histology, count of prior treatments, PDL1 expression, serum LDH levels, and the presence of liver, lung, or brain lesions.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>On univariable and multivariable analysis, baseline sum of the longest diameters of target lesions (SLD) was identified as significantly associated with OS (hazard ratio [95% confidence interval] per decimeter: 1.64 [1.41-1.91], P < .001) and PFS (1.21 [1.07-1.38], P = .003). Median OS were 16 months versus 10 months for baseline SLD < median, versus baseline SLD ≥ median, respectively. Median PFS were 4 months versus 3 months, respectively.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Large BTS was identified as an independent prognostic factor of worse OS and PFS, raising the need to evaluate atezolizumab as an earlier NSCLC treatment in future trials.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31735362</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2020</Year><Month>01</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8708</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>4-5</Issue><PubDate><MedlineDate>2019 Aug - Oct</MedlineDate></PubDate></JournalIssue><Title>Seminars in oncology</Title><ISOAbbreviation>Semin Oncol</ISOAbbreviation></Journal><ArticleTitle>Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors.</ArticleTitle><Pagination><MedlinePgn>380-384</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0093-7754(19)30127-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1053/j.seminoncol.2019.10.002</ELocationID><Abstract><AbstractText Label="BACKGROUND">Baseline tumor size (BTS) was recently indicated as prognostic of overall survival (OS) in patients advanced melanoma treated with pembrolizumab. We review the association between BTS and OS/progression-free survival (PFS) in patients with a diagnosis of advanced non-small-cell lung cancer (NSCLC) treated with atezolizumab.</AbstractText><AbstractText Label="METHODS">Data from 1,461 patients with a diagnosis of advanced NSCLC enrolled in the OAK, POPLAR, BIRCH, and FIR trials and treated with atezolizumab were pooled and analyzed. Using Cox proportional hazards regression, we modeled the association between baseline SLD and survival outcomes. Multivariable analyses were adjusted for pretreatment ECOG PS, age, sex, race, smoking status, histology, count of prior treatments, PDL1 expression, serum LDH levels, and the presence of liver, lung, or brain lesions.</AbstractText><AbstractText Label="RESULTS">On univariable and multivariable analysis, baseline sum of the longest diameters of target lesions (SLD) was identified as significantly associated with OS (hazard ratio [95% confidence interval] per decimeter: 1.64 [1.41-1.91], P < .001) and PFS (1.21 [1.07-1.38], P = .003). Median OS were 16 months versus 10 months for baseline SLD < median, versus baseline SLD ≥ median, respectively. Median PFS were 4 months versus 3 months, respectively.</AbstractText><AbstractText Label="CONCLUSIONS">Large BTS was identified as an independent prognostic factor of worse OS and PFS, raising the need to evaluate atezolizumab as an earlier NSCLC treatment in future trials.</AbstractText><CopyrightInformation>Copyright © 2019 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hopkins</LastName><ForeName>Ashley M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia. Electronic address: ashley.hopkins@flinders.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kichenadasse</LastName><ForeName>Ganessan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKinnon</LastName><ForeName>Ross A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowland</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorich</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>College of Medicine and Public Health, Flinders University, Adelaide, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Semin Oncol</MedlineTA><NlmUniqueID>0420432</NlmUniqueID><ISSNLinking>0093-7754</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance></Chemical><Chemical><RegistryNumber>52CMI0WC3Y</RegistryNumber><NameOfSubstance UI="C000594389">atezolizumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074322" MajorTopicYN="N">Antineoplastic Agents, Immunological</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056747" MajorTopicYN="N">Immunomodulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Atezolizumab</Keyword><Keyword MajorTopicYN="Y">Baseline tumor size</Keyword><Keyword MajorTopicYN="Y">Immune checkpoint inhibitors</Keyword><Keyword MajorTopicYN="Y">Progression</Keyword><Keyword MajorTopicYN="Y">Survival</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>07</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31735362</ArticleId><ArticleId IdType="pii">S0093-7754(19)30127-7</ArticleId><ArticleId IdType="doi">10.1053/j.seminoncol.2019.10.002</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li></country></list><tree><country name="Australie"><noRegion><name sortKey="Hopkins, Ashley M" sort="Hopkins, Ashley M" uniqKey="Hopkins A" first="Ashley M" last="Hopkins">Ashley M. Hopkins</name></noRegion><name sortKey="Kichenadasse, Ganessan" sort="Kichenadasse, Ganessan" uniqKey="Kichenadasse G" first="Ganessan" last="Kichenadasse">Ganessan Kichenadasse</name><name sortKey="Mckinnon, Ross A" sort="Mckinnon, Ross A" uniqKey="Mckinnon R" first="Ross A" last="Mckinnon">Ross A. Mckinnon</name><name sortKey="Rowland, Andrew" sort="Rowland, Andrew" uniqKey="Rowland A" first="Andrew" last="Rowland">Andrew Rowland</name><name sortKey="Sorich, Michael J" sort="Sorich, Michael J" uniqKey="Sorich M" first="Michael J" last="Sorich">Michael J. Sorich</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000621 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000621 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PoplarV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:31735362
|texte= Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:31735362" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PoplarV1
| This area was generated with Dilib version V0.6.37. |  |